Amneal Pharmaceuticals and Shilpa Medicare have launched the new presentation of bortezomib, Boruzu, for subcutaneous or ...

T2D has been associated with an increased risk of CV mortality and GLP-1RAs are being increasingly used as a T2D and obesity ...

At the BioTrinity Conference, experts champion government funding programmes to bridge gap the in UK venture capital ...

Apellis Pharmaceuticals has announced US FDA acceptance of the sNDA and the granting of priority review status to Empaveli ...

Organon has announced the acquisition from Biogen of US regulatory and commercial rights for intravenous infusion of ...

The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 to advance its RNA editing pipeline.

The push for reducing funding and the workforce at the FDA comes partly from US Secretary of Health and Human Services Robert ...

Panellists at the OBN BioTrinity 2025 conference in London discussed how US uncertainty is impacting the biopharma environment.

Plans outlined by HHS Secretary Robert F Kennedy, Jr look set to target jobs at the US Department of Health & Human Services (HHS).

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

A federal judge in Houston has rejected the third attempt by J&J subsidiary Red River to settle lawsuits related to its ...